A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator
The VICTORIA Trial
Paul W. Armstrong, Lothar Roessig, Mahesh J. Patel, Kevin J. Anstrom, Javed Butler, Adriaan A. Voors, Carolyn S.P. Lam, Piotr Ponikowski, Tracy Temple, Burkert Pieske, Justin Ezekowitz, Adrian F. Hernandez, Joerg Koglin and Christopher M. O'Connor
Restoration of Sufficient sGC-cGMP Signaling as Novel Target in HF
Endothelial dysfunction due to oxidative stress and inflammation reduces nitric oxide bioavailability leading to insufficient activation of sGC. The resulting cGMP deficiency is associated with myocardial dysfunction and impaired endothelium-dependent vasomotor regulation (pink). Vericiguat directly stimulates sGC in a NO-independent manner and by sensitizing the enzyme to endogenous NO (green). cGMP = cyclic guanosine monophosphate; HF = heart failure; NO = nitric oxide; sGC = soluble guanylate cyclase.